Inactive Instrument

Regulus Therapeutics Inc Stock price Nasdaq

Equities

US75915K1016

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * - Capitalization 189M
Net income 2024 * -33M Net income 2025 * -46M EV / Sales 2024 * -
Net cash position 2024 * 94.2M Net cash position 2025 * 50.8M EV / Sales 2025 * -
P/E ratio 2024 *
-5.67 x
P/E ratio 2025 *
-4.72 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.05%
More Fundamentals * Assessed data
Dynamic Chart
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target MT
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating MT
Top Midday Gainers MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell MT
Transcript : Regulus Therapeutics Inc. - Special Call
Top Premarket Gainers MT
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease CI
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease CI
Transcript : Regulus Therapeutics Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:25 AM
More news

Latest transcript on Regulus Therapeutics Inc

Managers TitleAgeSince
Chief Executive Officer 55 16-01-03
President 55 23-06-21
Director of Finance/CFO 54 19-08-29
Members of the board TitleAgeSince
Director/Board Member 57 17-05-31
Director/Board Member 86 08-12-31
Director/Board Member 75 13-03-31
More insiders
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company's lead product candidate includes RGLS8429. The Company is developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are complementary to (thereby pairing with) the target microRNA. RGLS8429 is an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). RGLS8429 maintains beneficial attributes, such as preferential kidney exposure and similar PK profile, miR-17 inhibition potency and duration of action in the kidney, equal potency in vitro and in vivo efficacy studies.
More about the company
  1. Stock
  2. Equities
  3. Stock Regulus Therapeutics Inc.
  4. Stock Regulus Therapeutics Inc - Nasdaq